NCT03305341View on ClinicalTrials.gov

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 18, 2025

Primary Completion Date

July 18, 2026

Study Completion Date

July 28, 2026

Conditions
Covid19
Interventions
BIOLOGICAL

COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use

"* By the percutaneous route with the multiple puncture device~* NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix"

Trial Locations (1)

20852

Medicine Invention Design Incorporation (MIDI) - IORG0007849, North Bethesda

All Listed Sponsors
collaborator

UnitedHealthcare

OTHER

lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY

NCT03305341 - Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix | Biotech Hunter | Biotech Hunter